Previous close | 315.60 |
Open | 315.20 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 312.00 - 316.00 |
52-week range | 299.01 - 430.00 |
Volume | |
Avg. volume | 6,157 |
Market cap | 254.895B |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | 16.23 |
EPS (TTM) | 19.22 |
Earnings date | N/A |
Forward dividend & yield | 9.97 (3.16%) |
Ex-dividend date | 17 Mar 2022 |
1y target est | 423.65 |
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tec
UnitedHealth Group, The Coca-Cola, Roche Holding, Lam Research and Valero Energy are part of the Zacks top analyst blog.